Drugs / Irradiated Allogeneic Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03272633 | Oct 2020 → Jun 2022 | RASopathy, acute lymphoblastic leukemia, acute myeloid leukemia, chromosome 17p deletion +6 | Rutgers, The State University of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irradiated Allogeneic Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03272633 ↗ |
| Modality | Cell therapy | “administration of irradiated haploidentical cells (IHC)” NCT03272633 ↗ |